[go: up one dir, main page]

MX2015013155A - Formulaciones farmaceuticas de la familia de la tetrandrina y metodo. - Google Patents

Formulaciones farmaceuticas de la familia de la tetrandrina y metodo.

Info

Publication number
MX2015013155A
MX2015013155A MX2015013155A MX2015013155A MX2015013155A MX 2015013155 A MX2015013155 A MX 2015013155A MX 2015013155 A MX2015013155 A MX 2015013155A MX 2015013155 A MX2015013155 A MX 2015013155A MX 2015013155 A MX2015013155 A MX 2015013155A
Authority
MX
Mexico
Prior art keywords
tetrandrine
pharmaceutical formulations
family
formulations
tetrandrine family
Prior art date
Application number
MX2015013155A
Other languages
English (en)
Inventor
Ron D Carroll
Original Assignee
Cba Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cba Pharma Inc filed Critical Cba Pharma Inc
Publication of MX2015013155A publication Critical patent/MX2015013155A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen las formulaciones farmacéuticas, los métodos y su uso en el tratamiento de trastornos utilizando formulaciones de sales de di-ácido puras del miembro de la familia de la tetrandrina, especialmente el di-clorhidrato de la d-tetrandrina combinando con un diluyente o portador farmacéutico. La presente invención se refiere a las formulaciones farmacéuticas de una familia de los alcaloides de bisbencilisoquinolina. La familia específica es denominada en la presente como la "familia de la tetrandrina".
MX2015013155A 2013-03-15 2014-03-06 Formulaciones farmaceuticas de la familia de la tetrandrina y metodo. MX2015013155A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361792849P 2013-03-15 2013-03-15
PCT/US2014/021195 WO2014149848A1 (en) 2013-03-15 2014-03-06 Tetrandrine family pharmaceutical formulations and method

Publications (1)

Publication Number Publication Date
MX2015013155A true MX2015013155A (es) 2016-04-04

Family

ID=51529969

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015013155A MX2015013155A (es) 2013-03-15 2014-03-06 Formulaciones farmaceuticas de la familia de la tetrandrina y metodo.

Country Status (7)

Country Link
US (4) US9517234B2 (es)
EP (1) EP2968310A4 (es)
JP (1) JP2016512818A (es)
KR (1) KR20150142691A (es)
CN (1) CN105358149A (es)
MX (1) MX2015013155A (es)
WO (1) WO2014149848A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10576077B2 (en) 2015-03-23 2020-03-03 Southwest Research Institute Pharmaceutical salt forms of Cepharanthine and Tetrandrine
CN107260694A (zh) * 2017-06-14 2017-10-20 广西大海阳光药业有限公司 一种治疗硅肺、风湿痛、关节痛及神经痛的长效新制剂
CN112402419B (zh) * 2019-08-23 2023-12-08 华东理工大学 海兰地嗪或其药学上可接受的盐在糖尿病或糖尿病并发症药物中的应用
CN111675717B (zh) * 2020-06-21 2023-04-07 兰州理工大学 粉防己单体化合物及其提取方法和用途
CN113456643B (zh) * 2021-08-11 2022-04-01 遵义医科大学 一种含普那布林的药物组合及其应用
CN114159438B (zh) * 2021-11-30 2023-07-18 首都医科大学附属北京安定医院 海兰地嗪及其衍生物在制备治疗抑郁症药物中的应用及所制备的抗抑郁药物

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4569852A (en) * 1983-08-23 1986-02-11 Warner-Lambert Company Maintenance of flavor intensity in pressed tablets
JPH0678232B2 (ja) * 1986-03-07 1994-10-05 株式会社ツムラ アンジオテンシンｉ転換酵素阻害剤
JPH0678231B2 (ja) * 1986-03-08 1994-10-05 株式会社ツムラ 血液粘度低下剤
JPH0733388B2 (ja) * 1987-01-22 1995-04-12 株式会社ツムラ 新規アルカロイド
JPH02243627A (ja) * 1989-03-16 1990-09-27 Tsumura & Co 狭心症治療薬
US6911454B1 (en) 1989-09-28 2005-06-28 Cancer Biologics Of America, Inc. Method for potentiating primary drugs in treating multidrug resistant disease
US5332747A (en) 1989-09-28 1994-07-26 Cancer Biologics Of America, Inc. Method for potentiating primary drugs in treating multidrug resistant parasitic disease cells
US5025020A (en) 1989-09-28 1991-06-18 Cancer Biologics Of America, Inc. Use of tetrandrine and its derivatives to treat malaria
JPH0499723A (ja) * 1990-08-17 1992-03-31 Kaken Shiyouyaku Kk ウイルス・ゲノム不活化剤
US5192802A (en) 1991-09-25 1993-03-09 Mcneil-Ppc, Inc. Bioadhesive pharmaceutical carrier
US5627195A (en) 1995-04-11 1997-05-06 Massachusetts Eye And Ear Infirmary Treatment for ocular inflammation
US6218541B1 (en) 1999-06-28 2001-04-17 Cba, International, Inc. Method for extracting bisbenzylisoquinolines
EP1175214B1 (en) * 1999-12-08 2004-11-24 Pharmacia Corporation Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
US20050245559A1 (en) * 2004-01-23 2005-11-03 Koul Hari K Treatment and prevention of prostate cancer
US20080045603A1 (en) * 2006-08-04 2008-02-21 John Devane Methods for treating at least one condition having MT1 receptor, 5HT2B receptor, and L-type calcium channel activity
US8247440B2 (en) * 2008-02-20 2012-08-21 Curators Of The University Of Missouri Composition comprising omeprazole, lansoprazole and at least one buffering agent
EP2241561A1 (en) 2009-04-16 2010-10-20 Neuron Biopharma, S.A. Neuroprotective, hypocholesterolemic and antiepileptic compound
US8609844B2 (en) 2009-11-05 2013-12-17 Cba Pharma, Inc. Method for extracting and purifying bisbenzylisoquinolines
EP2491930A1 (en) 2011-02-25 2012-08-29 Deva Holding Anonim Sirketi Pharmaceutical combination of betahistine and trimetazidine
EP2895168A4 (en) * 2012-09-13 2016-08-31 Cba Pharma Inc TETRANDRINE MEDICINAL FORMULATIONS AND METHOD
CN102898433B (zh) * 2012-09-26 2015-04-15 中国医药研究开发中心有限公司 一种汉防己甲素的没食子酸盐、其药物组合物、其制备方法及其用途
US20150238488A1 (en) * 2012-09-28 2015-08-27 Hangzhou Bensheng Pharmaceutical Co., Ltd. Drug composition for treating tumors and application thereof

Also Published As

Publication number Publication date
US20180298022A1 (en) 2018-10-18
EP2968310A4 (en) 2017-01-11
US9517234B2 (en) 2016-12-13
WO2014149848A1 (en) 2014-09-25
US20170050976A1 (en) 2017-02-23
US20170050975A1 (en) 2017-02-23
EP2968310A1 (en) 2016-01-20
US10023584B2 (en) 2018-07-17
JP2016512818A (ja) 2016-05-09
KR20150142691A (ko) 2015-12-22
US10815243B2 (en) 2020-10-27
CN105358149A (zh) 2016-02-24
US20140275137A1 (en) 2014-09-18

Similar Documents

Publication Publication Date Title
MX2015016983A (es) Moduladores del transporte nuclear y usos de los mismos.
BR112015021888A8 (pt) inibidores de dna-pk, seus usos e composição farmacêutica
MX2015012414A (es) Sal de omecamtiv mecarbilo y proceso para preparar la sal.
UA114907C2 (uk) Гетероциклільні сполуки як інгібітори mek
WO2014152029A3 (en) Oxazolo[5,4-c]quinolin-2-one compounds as bromodomain inhibitors
SG10201808102WA (en) Bicyclic heterocycle compounds and their uses in therapy
IN2014DN09434A (es)
EA201690093A1 (ru) Производные пирроло[3,2-d]пиримидина для лечения вирусных инфекций и других заболеваний
SG10201900648SA (en) Tablet formulation of 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide
EA201492040A1 (ru) Бициклически замещённые урацилы и их применение
EA201591679A1 (ru) Способ нетоксического лечения абстиненции, вызванной лекарственным средством
TN2016000006A1 (en) Benzyl-1h-pyrazolo[3,4-b]pyridines and use thereof
EA201691918A1 (ru) Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения
MX2015013155A (es) Formulaciones farmaceuticas de la familia de la tetrandrina y metodo.
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
WO2014106825A3 (en) Methods and devices for identifying improper medical reporting
MX2016008397A (es) Composicion para usarse en el tratamiento de tos persistente.
IN2013MU00711A (es)
MX2020001875A (es) Forma polimorfica de tg02.
PH12016502243A1 (en) Pharmaceutical compositions for treating infectious diseases
PH12017501071B1 (en) Dihydropyrimidin-2-one compounds and medical use thereof
MX357888B (es) Sales basicas de adicion de nitroxolina y usos de las mismas.
EA201600318A1 (ru) Циклические тиеноурацилкарбоксамиды и их применение
EA201790179A1 (ru) [1,2,4]триазоло[4,3-b]пиридазины для применения в лечении пролиферативных заболеваний
PH12018502111A1 (en) Ring-fused thiazolino 2-pyridones, methods for preparation thereof and their use in the treatment and/or prevention of tuberculosis